Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.
The company will have milestone news flow in coming months from its Phase II clinical trials for chronic kidney disease.
The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).
The innovative treatment combines two existing drugs.